Pathologic changes after photodynamic therapy for basal cell carcinoma and Bowen disease: A histologic and immunohistochemical investigation

Archives of Dermatology

Volumn 144, Issue 2, 2008, Pages 186-194

  Fantini, Fabrizio ^a   Greco, Antonietta ^a   Cesinaro, Anna Maria ^a   Surrenti, Tiziana ^b   Peris, Ketty ^b   Vaschieri, Cristina ^a   Marconi, Alessandra ^a   Giannetti, Alberto ^a   Pincelli, Carlo ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD20 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; DNA NUCLEOTIDYLEXOTRANSFERASE; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; EPIDERMIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SKIN BIOPSY; SKIN INFILTRATE; T LYMPHOCYTE;

AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; APOPTOSIS; BIOPSY; BOWEN'S DISEASE; CARCINOMA, BASAL CELL; CASPASE 3; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN NEOPLASMS;

EID: 39649086711     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archdermatol.2007.31     Document Type: Article

References (30)

1. Wolf P, Rieger E, Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of aminolevulinic acid: an alternative treatment modality for solar keratosis, superficial squamous cell carcinomas and basal cell carcinomas? J Am Acad Dermatol. 1993;28(1):17-21.
2. Calzavara-Pinton PG. Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma tumours. J Photochem Photobiol B. 1995;29(1):53-57.
3. Morton CA, Brown SB, Collins S, et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol. 2002;146(4):552-567.
4. Braathen LR, Szeimies RM, Basset-Seguin N, et al; International Society for Photodynamic Therapy in Dermatology. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol. 2007;56(1):125-143.
5. Oleinick NL, Morris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci. 2002;1(1):1-21.
6. Tosca AD, Balas CJ, Stefanidou MP, Katsantonis JC, Georgiou SK, Tzardi MN. Photodynamic treatment of skin malignancies with aminolevulinic acid: emphasis on anatomical observations and in vivo erythema visual assessment. Dermatol Surg. 1996;22(11):929-934.
7. Nakaseko H, Kobayashi M, Akita Y, Tamada Y, Matsumoto Y. Histological changes and involvement of apoptosis after photodynamic therapy for actinic keratoses. Br J Dermatol. 2003;148(1):122-127.
8. Boatright KM, Salvesen GS. Mechanisms of caspase activation. Curr Opin Cell Biol. 2003;15(6):725-731.
9. Salim A, Leman JA, McColl JH, Chapman R, Morton CA. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol. 2003;148(3):539-543.
10. Wang I, Bendsoe N, Klinteberg CAF, et al. Photodynamic therapy vs cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol. 2001;144(4):832-840.
11. Rhodes LE, de Rie M, Enström Y, et al. Photodynamic therapy using methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol. 2004;140(1):17-23.
12. Morton CA, MacKie RM, Whitehurst C, Moore JV, McColl JH. Photodynamic therapy for basal cell carcinoma: effect of tumor thickness and duration of photosensitizer application on response. Arch Dermatol. 1998;134(2):248-249.
13. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3(5):380-387.
14. Ochsner M. Photophysical and photobiological processes in the photodynamic therapy of tumours. J Photochem Photobiol B. 1997;39(1):1-18.
15. van Duijnhoven FH, Aalbers RIJM, Rovers JP, Terpstra OT, Kuppen PJK. The immunological consequences of photodynamic treatment of cancer: a literature review. Immunobiology. 2003;207(2):105-113.
16. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006;6(7):535-545.
17. Kessel D, Luo Y. Mitochondrial photodamage and PDT-induced apoptosis. J Photochem Photobiol B. 1998;42(2):89-95.
18. Nowis D, Makowski M, Stokłosa T, Legat M, Issat T, Gołab J. Direct tumor damage mechanisms of photodynamic therapy. Acta Biochim Pol. 2005;52(2):339-352.
19. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology. 1995;21(5):1465-1468.
20. Almeida RD, Manadas BJ, Carvalho AP, Duarte CB. Intracellular signaling mechanisms in photodynamic therapy. Biochim Biophys Acta. 2004;1704(2):59-86.
21. Szeimies RM, Sassy T, Landthaler M. Penetration potency of topical applied δ-aminolaevulinic acid for photodynamic therapy of basal cell carcinoma. Photochem Photobiol. 1994;59(1):73-76.
22. Peng Q, Warloe T, Moan J, et al. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem Photobiol. 1995;62(5):906-913.
23. Martin A, Tope WD, Grevelink JM, et al. Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment. Arch Dermatol Res. 1995;287(7):665-674.
24. Roberts DJ, Cairnduff F. Photodynamic therapy of primary skin cancer: a review. Br J Plast Surg. 1995;48(6):360-370.
25. Peng Q, Soler AM, Warloe T, Nesland JM, Giercksky KE. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B. 2001;62(3):140-145.
26. He J, Agarwal ML, Larkin HE, Friedman LR, Xue LY, Oleinick NL. The induction of partial resistance to photodynamic therapy by the protooncogene Bcl-2. Photochem Photobiol. 1996;64(5):845-852.
27. Zhang WG, Ma LP, Wang SW, Zhang ZY, Cao GD. Antisense Bcl-2 retrovirus vector increases the sensitivity of a human gastric adenocarcinoma cell line to photodynamic therapy. Photochem Photobiol. 1999;69(5):582-586.
28. Srivastava M, Ahmad N, Gupta S, Mukhtar H. Involvement of Bcl-2 and Bax in photodynamic therapy mediated apoptosis: antisense Bcl-2 oligonucleotide sensitizes RIF 1 cells to photodynamic therapy apoptosis. J Biol Chem. 2001;276(18):15481-15488.
29. Xue LY, Chiu SM, Oleinick NL. Photochemical destruction of the Bcl-2 oncoprotein during photodynamic therapy with the phthalocyanine photosensitizer Pc 4. Oncogene. 2001;20(26):3420-3427.
30. Vidal D, Matias-Guiu X, Alomar A. Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. Br J Dermatol. 2004;151(3):656-662.